SCHEMBL5031348

SCHEMBL5031348

CCCCc1nc2c(c(C)c(C)n3nnnc23)n1CC(C)(C)NC(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 17/20 0.39
TLR8 Q9NR97 7/20 0.39
POLB P06746 1/20 0.35
AGTR2 P50052 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031326 0.95 TLR7 (0.38) TLR7TLR8POLBAGTR2
SCHEMBL5030440 0.89 TLR7 (0.36) TLR7TLR8
SCHEMBL5031349 0.84 TLR7 (0.37) TLR7TLR8
SCHEMBL5030358 0.80 TLR7 (0.52) TLR7TLR8
SCHEMBL5030389 0.80 TLR8 (0.33) TLR7TLR8
SCHEMBL5030376 0.78 TLR7 (0.39) TLR7TLR8
SCHEMBL5031379 0.75 TLR7 (0.46) TLR7TLR8
SCHEMBL1490240 0.74 HTR1A (0.41) TLR7
SCHEMBL5034584 0.72 EPHX1 (0.36)
SCHEMBL5347617 0.71 TP53 (0.41) TLR7TLR8POLBAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885POLB 1618/4885
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885POLB 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.